Checking in on hypoxia/reoxygenation

Cell Cycle

Volumn 5, Issue 12, 2006, Pages 1304-1307

  Freiberg, Rachel A ^a   Krieg, Adam J ^a   Giaccia, Amato J ^a   Hammond, Ester M ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

ATM; Chk 2; Hypoxia; Reoxygenation

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BRCA1 PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

CELL CYCLE ARREST; CELL CYCLE G2 PHASE; DNA DAMAGE; HYPOXIA; PHOSPHORYLATION; PHYSIOLOGICAL STRESS; REOXYGENATION; REVIEW;

EID: 33745148690     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.12.2811     Document Type: Review

References (41)

1. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864-70.
2. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio Jr RA, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-13.
3. Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, Knapstein PG, Vaupel P. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993; 26:45-50.
4. Hockel M, Knoop C, Schlenger K, Vorndran B, Knapstein PG, Vaupel P. Intratumoral pO2 histography as predictive assay in advanced cancer of the uterine cervix. Adv Exp Med Biol 1994; 345:445-50.
5. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56:4509-15.
6. Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999; 59:4525-8.
7. Hockel M, Schlenger K, Mitze M, Schaffer U, Vaupel P. Hypoxia and radiation response in human tumors. Semin Radiat Oncol 1996; 6:3-9.
8. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001; 28:36-41.
9. Hockel M, Vaupel P. Oxygenation of cervix cancers: Impact of clinical and pathological parameters. Adv Exp Med Biol 2003; 510:31-5.
10. Vaupel P, Hockel M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: Characterization and therapeutic relevance. Int J Oncol 2000; 17:869-79.
11. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 1989; 49:6449-65.
12. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001; 28:29-35.
13. Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human tumors: Evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991; 51:3316-22.
14. Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ. Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol 2002; 22:1834-43.
15. Hammond EM, Giaccia AJ. The role of ATM and ATR in the cellular response to hypoxia and reoxygenation. DNA Repair (Amst) 2004; 3:1117-22.
16. Freiberg RA, Hammond EM, Dorie MJ, Welford SM, Giaccia AJ. DNA damage during reoxygenation elicits a Chk2-dependent checkpoint response. Mol Cell Biol 2006; 26:1598-609.
17. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421:499-506.
18. Goodarzi AA, Jonnalagadda JC, Douglas P, Young D, Ye R, Moorhead GB, Lees-Miller SP, Khanna KK. Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. Embo J 2004; 23:4451-61.
19. Matsuoka S, Nakagawa T, Masuda A, Haruki N, Elledge SJ, Takahashi T. Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. Cancer Res 2001; 61:5362-5.
20. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286:2528-31.
21. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K, Nevanlinna H. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: Further evidence of CHK2 in inherited cancer predisposition. Cancer Res 2001; 61:5718-22.
22. Bartkova J, Guldberg P, Gronbaek K, Koed K, Primdahl H, Moller K, Lukas J, Orntoft TF, Bartek J. Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer. Oncogene 2004; 23:8545-51.
23. Staalesen V, Falck J, Geisler S, Bartkova J, Borresen-Dale AL, Lukas J, Lillehaug JR, Bartek J, Lonning PE. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene 2004; 23:8535-44.
24. 2 checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997; 277:1501-5.
25. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998; 282:1893-7.
26. Gibson SL, Bindra RS, Glazer PM. Hypoxia-induced phosphorylation of Chk2 in an ataxia telangiectasia mutated-dependent manner. Cancer Res 2005; 65:10734-41.
27. Stewart GS, Maser RS, Stankovic T, Bressan DA, Kaplan MI, Jaspers NG, Raams A, Byrd PJ, Petrini JH, Taylor AM. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 1999; 99:577-87.
28. Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003; 22:5612-21.
29. 2/M checkpoints are induced by ionizing irradiation. Mol Cell Biol 2002; 22:1049-59.
30. 1 checkpoint control manipulation to modulation of p53-mediated apoptosis. Oncogene 1998; 16:957-66.
31. Tercero JA, Longhese MP, Diffley JF. A central role for DNA replication forks in checkpoint activation and response. Mol Cell 2003; 11:1323-36.
32. 2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004; 3:513-9.
33. Zhou BB, Bartek J. Targeting the checkpoint kinases: Chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4:216-25.
34. Green SL, Freiberg RA, Giaccia AJ. p21(Cip1) and p27(Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol Cell Biol 2001; 21:1196-206.
35. Sonoda E, Sasaki MS, Buerstedde JM, Bezzubova O, Shinohara A, Ogawa H, Takata M, Yamaguchi-Iwai Y, Takeda S. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J 1998; 17:598-608.
36. Rahman N, Stratton MR. The genetics of breast cancer susceptibility. Annu Rev Genet 1998; 32:95-121.
37. Lee JS, Collins KM, Brown AL, Lee CH, Chung JH. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 2000; 404:201-4.
38. Zhang J, Willers H, Feng Z, Ghosh JC, Kim S, Weaver DT, Chung JH, Powell SN, Xia F. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 2004; 24:708-18.
39. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4:665-76.
40. Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, Bristow RG, Classon MK, Glazer PM. Hypoxia-induced downregulation of BRCA1 expression by E2Fs. Cancer Res 2005; 65:11597-604.
41. Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002; 1:453-8.